Key findings:

• A single dose of 25 mg of psilocybin was administered to participants.
• Brain structure changes were evident even one month after taking psilocybin.
• EEG results indicated a surge in brain entropy within an hour of taking the drug.

Prof. Robin Carhart-Harris noted, “It’s remarkable to see potential anatomical brain changes one month after a single dose of any drug.” This study contributes to the growing body of research on psychedelics and their effects on mental health.

The Functional Mushroom Council, established in 2025, aims to unify North American growers and suppliers in promoting functional mushrooms. Recently, they welcomed new members including Unicorn Bags and Maine Cap N’ Stem.

In related developments, M2 Ingredients launched M2Brew, a functional mushroom ingredient designed for brewed coffee applications. Additionally, Fungi Perfecti introduced several product lines such as Grateful Dead Gummies and Host Defense Gummies. Monterey Nutra also debuted ManeFocus, a premium Lion’s Mane extract noted for its high bioavailability.

The post Mushroom study shows lasting brain changes from psilocybin appeared first on cottenhamnews.

In 1962, Lotsof discovered that ibogaine cured his heroin addiction. His experience sparked interest in the substance, leading to unsanctioned use across the United States. Fast forward to today, and ibogaine is again at the forefront of discussions around addiction treatment, thanks in part to endorsements from figures like Joe Rogan and Donald Trump.

On April 18, 2026, an executive order was signed directing the FDA to facilitate access to psychedelic drugs, including ibogaine compounds. This development reflects a growing recognition of the therapeutic potential of psychedelics. The executive order also includes a financial commitment—$50 million allocated by the Department of Health for developing programs aimed at serious mental illnesses.

Texas has also made strides; last year, it approved $50 million specifically for ibogaine research. These investments underscore a shift towards more formalized research and potential regulatory approval for ibogaine as a treatment option.

The experience of ibogaine treatment typically lasts between 12 to 36 hours, during which patients often report vivid visions and a significant reduction in withdrawal symptoms and cravings. Such reports are compelling but come with caveats given the documented fatalities associated with its use.

The post Ibogaine: A New Frontier in Addiction Treatment appeared first on cottenhamnews.